Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Ltd. has disclosed a change in director Dr. Christian Behrenbruch’s interests, reporting an acquisition of 144,037 Performance Share Appreciation Rights (PSARs) valued at approximately $856,158. These rights, part of his FY24 remuneration and subject to performance hurdles, were approved at the company’s AGM on May 22, 2024. Dr. Behrenbruch also holds over 22 million shares indirectly through a family trust and a direct interest in over 550,000 shares and various options.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
